Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255376 | 0.74 | NPC1 (0.32) | — | |
| SCHEMBL3188143 | 0.73 | PARP1 (0.47) | XDHSLC22A12 | |
| SCHEMBL943134 | 0.72 | PARP1 (0.31) | — | |
| SCHEMBL944599 | 0.72 | PARP1 (0.31) | — | |
| SCHEMBL23199575 | 0.67 | XDH (0.34) | XDHSLC22A12 | |
| SCHEMBL20424920 | 0.64 | XDH (0.32) | XDH | |
| SCHEMBL31344845 | 0.63 | XDH (0.33) | XDHSLC22A12 | |
| SCHEMBL25366255 | 0.63 | PARP1 (0.36) | XDHSLC22A12 | |
| SCHEMBL4695076 | 0.63 | PARP1 (0.38) | — | |
| SCHEMBL24517017 | 0.63 | PRKCI (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781669-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | claimed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | claimed |
| US-20080194547-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | claimed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | claimed |
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | claimed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | claimed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | claimed |
| EP-1781669-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-09 | — | — | EP | claimed |
| EP-1778688-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-02 | — | — | EP | claimed |
| EP-1773831-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | claimed |
| EP-1773847-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017468-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | claimed |
| WO-2006014580-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-09 | — | — | WO | claimed |
| WO-2006012396-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | WO | claimed |
| WO-2006010040-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | claimed |
| US-8513260-B2 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-20 | — | — | US | disclosed |
| WO-2006010040-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | XDH 306/4885SLC22A12 4173/4885 |
| US-20070244091-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | XDH 112/4885SLC22A12 2562/4885 |
| US-20070270417-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | XDH 132/4885SLC22A12 2515/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | XDH 112/4885SLC22A12 2562/4885 |
| US-20080194547-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | XDH 380/4885SLC22A12 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.